Gene therapy for lysosomal storage diseases
AssigneeGenzyme Corporation
InventorsJames Dodge, Seng Cheng
Life of this patent
Estimating the term…
Abstract
This disclosure provides methods and compositions for treating lysosomal storage diseases in a subject. In one aspect of the invention, a transgene product is delivered to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the subject's brain. The transgene product may be any that is deficient in a lysosomal storage disease.
Claims7
A method to deliver acid beta glucosidase to the central nervous system in a subject having Gaucher disease, comprising:
- administering a recombinant AAV4 or AAV5 viral vector comprising a transgene encoding acid beta glucosidase to at least one ventricle of the brain selected from the group consisting of a lateral ventricle and the fourth ventricle by intraventricular administration, whereby said transgene is expressed and acid beta glucosidase is delivered to the central nervous system, wherein the subject is a mammal.
Dependencies are inferred from the claim text.